Navigation Links
Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
Date:8/16/2010

$73.8 million as of March 31, 2010. Total assets as of June 30, 2010, were $96.7 million compared with $98.7 million at March 31, 2010. The Company had $13.8 million in outstanding debt at the end of the second quarter, compared with $15.3 million at March 31, 2010. A large majority of proceeds from the Company's initial public offering remains available for planned portfolio expansion as well as continued development of currently marketed products.

"We are pleased to have achieved top line revenue growth in the second quarter and are committed to building our three marketed products while we pursue new portfolio additions," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Our business development and product development teams are evaluating several new product opportunities. We also remain acutely focused on expanding hospital formulary approval for Caldolor and have taken a fresh look at the market and our strategy to build that brand for long-term success."

Cumberland is providing full year 2010 revenue guidance, which represents the Company's best estimate of likely future results and which may be affected by factors described below in "Forward-Looking Statements." The Company expects its net revenue for the twelve-month period ended December 31, 2010, to be between $42 and $43 million.

QUARTER HIGHLIGHTSProduct DevelopmentSupplemental New Drug Application for Acetadote

In March 2010, Cumberland submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for use of Acetadote in patients with non-acetaminophen induced acute liver failure. The sNDA included data from a clinical trial at the University of Texas Southwestern Medical Center indicating that acute liver failure patients treated with Acetadote have a significantly improved chance of survival without transplant, and that patients requiring transplant can survive a number of days longer without transpla
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
2. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
3. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
4. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
5. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
6. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
7. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
8. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
9. Ferring Pharmaceuticals FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
10. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
11. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... BARCELONA, Spain , September 2, 2014 ... treatment decisions, including patients, quality of life and treatment ... [ 2 ]   ... ESC Congress 2014, 02 September 2014, ... year results of the PREvention oF thromboembolic events-European Registry ...
(Date:9/2/2014)... , Sept. 2, 2014  Edison Nation Medical, ... partnership with the American Association for Respiratory Care ... respiratory care specialists. Edison Nation Medical, which brings ... business to commercialize their innovation ideas, will work ... of more than 50,000 respiratory therapists in bringing ...
(Date:9/2/2014)... 2, 2014  EMD Serono, Inc., a subsidiary of ... today that Drew Young has joined the ... this capacity, he will be responsible for leading the ... including future products.   Bringing more than 20 ... sales efforts at pharmaceutical and biotech companies, Mr. Young ...
Breaking Medicine Technology:One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4
... presented at the 10th International Kidney Cancer Symposium ... pretreatment blood-based test, VeriStrat, was able to stratify ... combination of two targeted therapies, sunitinib (Sutent®) and ... tested VeriStrat Good had significantly longer progression free ...
... 14, 2011 Reata Pharmaceuticals, Inc. announced Friday a ... company,s lead program, bardoxolone methyl, and to continue advancing ... the following executives: Paul Audhya, MD, ... Hilary Malone, Ph.D., as Vice President and ...
Cached Medicine Technology:VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 2VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 3Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 2Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 3
(Date:9/3/2014)... An inspiring story of the importance ... the season finale of “Extreme Weight Loss” Season Four. ... daughter from Highlands Ranch, Colo. who have a strained ... pounds. Their challenge is to team up to lose ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:9/3/2014)... 03, 2014 Health information technology ... safety, decreases medical errors, and strengthens the interaction ... mark the important role health information technology plays ... others across the U.S. have joined together to ... September 16-20, 2014. With the NHIT Week theme: ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 Independent ... use of appropriate evidence-based health care along the ... benefit from the expertise of accredited independent review ... health care system. , As a core function, ... often settle questions of medical necessity. Yet backed ...
(Date:9/2/2014)... IMCA Speedway Motors Super Nationals, presented by Casey’s ... at the IMCA Speedway in Boone, Iowa. On ... check presentation to Hope For The Warriors® ( http://www.hopeforthewarriors.org ... organization that assists post-9/11 service members, their families, and ... psychological wounds in the line of duty. ...
(Date:9/2/2014)... PULLMAN, Wash. - Smoking today,s concentrated pot might ... research from Washington State University. The study is ... development of tolerance to THC. , Psychology ... estrogen levels, female rats are at least 30 ... qualities of THCthe key active ingredient in cannabis. ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3Health News:IMCA to Present Donation to Hope For The Warriors 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3
... , , ATLANTA, ... related to the diagnosis and treatment of infertility with ovulation induction ... emotional, scientific and financial aspects. Discussions include information about age related ... donor sperm or donor eggs. , , ...
... , , ... officials announced today that Tennessee residents have saved over $7.3 million ... the free statewide prescription assistance program. Tennessee Drug Card, which ... 2007. The program has no restrictions to membership, no income requirements, ...
... , , MINNEAPOLIS, July 27 ... world,s population, often resulting in patches of dry skin, and little red ... the teenage years but may continue throughout adulthood. There is no ... B. Fleischer, professor and chair of the department of dermatology at Wake ...
... exercise at lower concentrations , MONDAY, July 27 (HealthDay ... have a negative effect on lung function in healthy people, ... allows for ozone concentrations of up to 75 parts per ... that 6.6 hours exposure to mean ozone concentrations as low ...
... , LA JOLLA, Calif., July 27 For the ... business leaders, community members and cancer survivors "surfing for a cure" ... held at UC San Diego,s Scripps Institution of Oceanography. Now, members ... Longboard Invitational portion of the event that takes place on Sunday, ...
... New York, NY The Lymphoma Research Foundation (LRF) is ... Research Foundation Clinical Investigator Career Development Award has been ... the Nebraska Medical Center in Omaha, Nebraska. ... is broadly categorized into Hodgkin lymphoma (HL) and non-Hodgkin ...
Cached Medicine News:Health News:Tennessee Drug Card Has Saved Residents Over $7.3 Million 2Health News:What Is Keratosis Pilaris (KP)? 2Health News:'Safe' Ozone Levels May Not Be for Some 2Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 2Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 3Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 4Health News:Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research 2
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: